Novartis Ag (NYSE: NVS)
Novartis Ag Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Novartis Ag Company Info
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
News & Analysis
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move
Novartis is taking a more calculated and strategic approach to its growth.
Why Novartis Stock Is Down Today Despite Topping Q2 Estimates
Investors were caught off guard by a decision on the research and development front.
2 Magnificent Dividend Stocks to Hold for the Next Decade
The dividend is just one reason to buy these stocks.
Why Novartis Stock Topped the Market on Tuesday
A double beat on the latest quarterly results and raised guidance made investors happy.
1 Magnificent Dividend Stock to Buy and Hold
The company's business went through some important changes last year.
2 Dividend Stocks to Buy and Hold Forever
These businesses look too strong to fail.
3 No-Brainer Stocks to Buy for Under $100 Right Now
A couple of these stocks might not be available for under $100 for too much longer.
2 Green Flags and 1 Red Flag for Novartis Stock
The Swiss pharmaceutical company just posted strong Q3 numbers and is going through some big changes.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.